세계의 유방암 치료제 시장 규모 : 병용 치료별, 환자 연령층별, 개발 프로세스별, 지역별, 범위 및 예측

Breast Cancer Drugs Market Size And Forecast

Breast Cancer Drugs Market size was valued at USD 30.65 Billion in 2023 and is projected to reach USD 111.14 Billion by 2031, growing at a CAGR of 19.27% from 2024 to 2031. Breast cancer drugs are used in the treatment and management of various types and stages of breast cancer which remains one of the most common cancers affecting women worldwide. These drugs include chemotherapy agents, hormonal therapies, targeted therapies, and immunotherapies each aimed at treating the disease in different ways depending on the type and severity of the cancer. They are used to treat various stages of the disease including early-stage, advanced, and metastatic breast cancer. These drugs include hormone therapies, chemotherapy agents, targeted therapies, and immunotherapies which help shrink tumors, reduce recurrence risks, and improve patient outcomes. Applications also extend to neoadjuvant therapies (before surgery) and adjuvant therapies (after surgery) to enhance the effectiveness of treatments.

The breast cancer drugs market is expected to continue growing as the demand for newer, more effective therapies rises. Advancements in personalized medicine and biotechnology are leading to the development of drugs that target specific genetic mutations such as BRCA mutations. Additionally, there is ongoing research into improving immunotherapy options that harness the body's immune system to fight cancer.

Global Breast Cancer Drugs Market Dynamics

The key market dynamics that are shaping the global breast cancer drugs market include:

Key Market Drivers:

Rising Breast Cancer Incidence

: The increasing prevalence of breast cancer globally is a primary driver of market demand. According to the World Health Organization (WHO), breast cancer is the most common cancer worldwide, leading to a high demand for effective treatment options.

Advancements in Drug Development

: Continuous innovation in breast cancer treatments such as targeted therapies, hormone therapies, and immunotherapies, has significantly improved patient outcomes driving the market forward. Personalized medicine is becoming a key trend in this space allowing for tailored treatments that are more effective for individual patients based on their genetic profiles.

Government Initiatives and Funding

: Governments and healthcare organizations across the world are investing heavily in breast cancer awareness, early detection programs, and treatment accessibility which boosts the demand for breast cancer drugs. Initiatives aimed at funding research and providing support for clinical trials have led to the development of newer, more effective therapies.

Key Challenges:

High Treatment Costs

: The cost of advanced breast cancer drugs, particularly targeted therapies and immunotherapies can be prohibitive, limiting accessibility in low-income regions and posing a challenge to market expansion. This cost barrier can prevent patients from receiving the necessary treatments promptly, potentially affecting their outcomes.

Adverse Side Effects

: Some breast cancer drugs are associated with severe side effects leading to concerns among patients and healthcare providers about their use, which can restrain market growth. These side effects may include nausea, fatigue, and increased risk of infections which can deter patients from adhering to treatment plans.

Regulatory Approvals

: The stringent regulatory approval process for new cancer drugs can delay product launches challenging manufacturers to navigate complex regulatory environments. Companies must invest significant resources into clinical trials and compliance which can prolong the time to market and increase development costs.

Key Trends:

Personalized Medicine and Targeted Therapies:

There is a significant shift towards personalized medicine in the treatment of breast cancer. Advances in genomics and molecular profiling allow for the development of targeted therapies that specifically address the unique genetic mutations present in individual tumors. This approach enhances treatment efficacy and reduces side effects leading to improved patient outcomes. For example, therapies targeting HER2-positive breast cancer such as trastuzumab and neratinib are becoming increasingly popular showcasing the trend towards tailored treatment plans based on a patient's specific cancer characteristics.

Immunotherapy Advancements:

Immunotherapy is gaining traction as a promising treatment modality for breast cancer. New therapies that harness the body's immune system to fight cancer cells are emerging, offering hope for patients with aggressive or metastatic forms of the disease. Checkpoint inhibitors, such as pembrolizumab, are being explored in clinical trials and are showing positive results in combination with traditional therapies.

Increased Focus on Patient Support and Accessibility

: There is a growing emphasis on improving patient support systems and ensuring accessibility to breast cancer drugs. Healthcare providers and pharmaceutical companies are increasingly recognizing the importance of holistic patient care which includes not only effective treatment but also support services, counseling, and educational resources.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Breast Cancer Drugs Market Regional Analysis

North America

North America stands out as a leading market for breast cancer drugs fueled by several pivotal factors. The region is characterized by a high incidence of breast cancer with estimates indicating that over 280,000 new cases will be diagnosed in 2023 alone. This high prevalence underscores the pressing need for effective treatment solutions and has prompted significant investment in research and development of innovative therapies.

The robust healthcare infrastructure in North America plays a critical role in supporting advancements in breast cancer treatments. The United States has a well-established healthcare system enabling patients to access cutting-edge therapies and participate in clinical trials for new drugs.

Additionally, the significant investments in oncology research further drive market growth. The National Cancer Institute and other organizations fund numerous studies aimed at improving breast cancer outcomes. These efforts focus on understanding the disease at a molecular level which leads to the development of more effective and tailored treatment options.

Asia Pacific

The Asia Pacific region is emerging as a significant player in the global breast cancer drugs market due to several compelling factors. Firstly, the rising incidence of breast cancer in countries such as China and India is alarming with statistics indicating that breast cancer is now the most prevalent cancer among women in these nations. This increase can be attributed to lifestyle changes, genetic predispositions, and environmental factors.

Furthermore, healthcare expenditure in the region is on the rise driven by government initiatives aimed at enhancing healthcare access and quality. Countries in the Asia Pacific are investing heavily in healthcare infrastructure which is crucial for improving cancer detection, treatment, and care services. For instance, China has implemented national cancer screening programs and increased funding for oncology research which encourages the development of effective breast cancer treatments.

Moreover, increased awareness regarding breast cancer prevention and treatment is fostering a proactive approach among the population. Public health campaigns and education initiatives are helping women recognize the importance of early detection through regular screenings and self-examinations.

Global Breast Cancer Drugs Market: Segmentation Analysis

The Global Breast Cancer Drugs Market is segmented based on Combination Treatments, Age Group of the Patient, Drug Development Process, and Geography.

Breast Cancer Drugs Market, By Combination Treatments

• Chemotherapy with Targeted Therapy
• Hormonal Therapy with Chemotherapy
• Targeted Therapy with Immunotherapy

Based on the Combination Treatments, the Global Breast Cancer Drugs Market is bifurcated into Chemotherapy with Targeted Therapy, Hormonal Therapy with Chemotherapy, and Targeted Therapy. Immunotherapy market is significantly driven by the use of chemotherapy in conjunction with targeted therapy. This combination is particularly effective for patients with advanced-stage breast cancer where multi-faceted approaches are required to enhance therapeutic efficacy. Chemotherapy combined with targeted therapy such as HER2 inhibitors has shown promising results in improving survival rates and reducing tumor size. Hormonal therapy when used alongside chemotherapy, is also prevalent, especially for hormone receptor-positive patients as it addresses both hormonal and cellular mechanisms of cancer progression.

Breast Cancer Drugs Market, By Age Group of the Patient

• Under 40 Years

40-60 Years

• Above 60 Years

Based on the Age Group of the Patient, The Global Breast Cancer Drugs Market is bifurcated into Under 40 Years, 40-60 Years, and Above 60 Years. The 40-60 years age group represents a significant portion of breast cancer patients, often diagnosed with varying types and stages of cancer. This demographic benefits from tailored treatment regimens that address both the aggressiveness of the cancer and the patient's overall health status. Younger patients (under 40 years) are increasingly being recognized for their unique treatment challenges, as they may require more aggressive treatment options and may have different fertility preservation considerations. For patients above 60 years, treatment strategies often focus on balancing efficacy with the management of comorbidities emphasizing the need for personalized approaches that consider both the cancer and the patient's age-related health concerns.

Breast Cancer Drugs Market, By Drug Development Process

• Preclinical Phase
• Clinical Trials Phase
• Regulatory Approval Phase

Based on the Drug Development Process the market is divided into Preclinical Phase, Clinical Trials Phase, and Regulatory Approval Phase. The preclinical phase encompasses research and development activities where potential drug candidates are evaluated for efficacy and safety. Significant investments in this phase have led to the discovery of novel compounds and innovative therapies. The clinical trials phase is equally important as it involves rigorous testing in human subjects to establish the safety and effectiveness of new treatments. The successful transition from clinical trials to regulatory approval is a key driver of market growth as it facilitates the introduction of new therapies into the market.

Breast Cancer Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Global Breast Cancer Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant market for breast cancer drugs driven by high incidence rates and advanced healthcare infrastructure. The United States invests heavily in cancer research resulting in the rapid development and approval of new breast cancer therapies. Additionally, a strong emphasis on early detection and treatment strategies further supports market growth in this region. Europe also plays a significant role in the market supported by increasing awareness and initiatives for breast cancer screening and treatment. Meanwhile, the Asia Pacific region is experiencing notable growth, fueled by rising healthcare expenditures, improved access to treatments, and a growing awareness of breast cancer, particularly in emerging markets like India and China.

Key Players

• The "Global Breast Cancer Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Merck & Co., Inc., Bristol Myers Squibb Company, Pfizer Inc., Roche Holding AG, Eli Lilly and Company, Novartis International AG, AstraZeneca PLC, Sanofi S.A., F. Hoffmann-La Roche Ltd., Seattle Genetics, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Breast Cancer Drugs Market Key Developments

• In September 2023, Merck announced positive clinical trial results for Keytruda in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC). The trial demonstrated a significant increase in progression-free survival compared to chemotherapy alone, solidifying Keytruda's role in the treatment landscape for aggressive breast cancer types.
• In December 2023, Bristol Myers Squibb received FDA approval for a new combination therapy involving Abraxane and Erbitux for patients with metastatic breast cancer. This combination showed promising results in clinical trials, particularly in patients with EGFR-positive tumors, offering a new treatment option for those who have exhausted other therapies.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BREAST CANCER DRUGS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BREAST CANCER DRUGS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BREAST CANCER DRUGS MARKET, BY COMBINATION TREATMENTS

• 5.1 Overview
• 5.2 * Chemotherapy with Targeted Therapy
• 5.3 * Hormonal Therapy with Chemotherapy
• 5.4 * Targeted Therapy with Immunotherapy

6 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP OF THE PATIENT

• 6.1 Overview
• 6.2 * Under 40 Years
• 6.3 * 40-60 Years
• 6.4 * Above 60 Years

7 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG DEVELOPMENT PROCESS

• 7.1 Overview
• 7.2 * Preclinical Phase
• 7.3 * Clinical Trials Phase
• 7.4 * Regulatory Approval Phase

8 GLOBAL BREAST CANCER DRUGS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East

9 GLOBAL BREAST CANCER DRUGS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Merck & Co., Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Bristol Myers Squibb Company
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Pfizer Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Roche Holding AG
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Eli Lilly and Company
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Novartis International AG
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 AstraZeneca PLC
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Sanofi S.A.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 F. Hoffmann-La Roche Ltd.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Seattle Genetics, Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research